Stem cells are undifferentiated cells capable of self-renewal (producing identical daughter cells) and differentiation (producing specialized cell types). They maintain and repair tissues throughout life. Understanding their histological identification and biological properties is fundamental to developmental biology and regenerative medicine.
Types of Stem Cells
Embryonic stem cells (ESCs) — derived from the inner cell mass of the blastocyst. They are pluripotent — capable of differentiating into all three germ layers (ectoderm, mesoderm, endoderm). ESCs form teratomas (tumors containing tissues from all three germ layers) when injected into immunodeficient mice — this is the defining functional test of pluripotency.
Adult (somatic) stem cells — multipotent stem cells found in most tissues, responsible for physiological turnover and injury repair. They are typically rare (1 in 10,000 to 1 in 100,000 cells) and reside in specialized microenvironments called niches.
Induced pluripotent stem cells (iPSCs) — adult somatic cells reprogrammed to pluripotency by forced expression of transcription factors (OCT4, SOX2, KLF4, MYC — the “Yamanaka factors”). iPSCs are morphologically and functionally similar to ESCs but avoid ethical concerns and enable patient-specific cell therapy.
Histological Identification of Stem Cells
Stem cells lack distinctive morphological features on H&E — they appear as small, undifferentiated cells with high nuclear-to-cytoplasmic ratio, prominent nucleoli, and sparse cytoplasm. They are identified by: location (stem cell niches), IHC markers, and functional assays.
IHC markers of pluripotency: OCT4 (POU5F1) — the master regulator of pluripotency, nuclear expression in ESCs and iPSCs; SOX2 — co-expressed with OCT4, essential for maintaining pluripotency and neural stem cell identity; NANOG — homeobox transcription factor required for inner cell mass formation; SSEA3/SSEA4 (stage-specific embryonic antigens) — glycolipids on ESC surfaces; TRA-1-60/TRA-1-81 — keratan sulfate proteoglycans on ESC surfaces. In tissue sections, OCT4 and NANOG are also expressed in germ cell tumors (seminoma, dysgerminoma, embryonal carcinoma).
Adult Stem Cell Niches
Hematopoietic stem cell (HSC) niche — bone marrow endosteal and perivascular niches. HSCs are identified by CD34, CD133, c-KIT (CD117), and lack of lineage markers (Lin-). HSCs are rare (~0.01% of marrow cells) but generate all blood cell lineages.
Intestinal stem cell niche — crypt base columnar cells (Lgr5+ cells) at the base of intestinal crypts. They generate all intestinal epithelial lineages (enterocytes, goblet cells, Paneth cells, enteroendocrine cells) and turn over every 4-5 days. Metaplastic and dysplastic changes in intestinal epithelium are traced to stem cell alterations.
Skin stem cell niche — bulge region of hair follicles (CD34+, K15+) and interfollicular epidermis (basal layer). These cells regenerate epidermis, hair follicles, and sebaceous glands during wound healing.
Neural stem cell (NSC) niche — subventricular zone (SVZ) of the lateral ventricles and subgranular zone (SGZ) of the hippocampal dentate gyrus. NSCs express Nestin, SOX2, and GFAP (in SVZ). Neurogenesis persists throughout life but declines with age.
Stem Cells in Tissue Repair
Liver regeneration — hepatocytes themselves are the primary regenerative cell (not a dedicated stem cell). After partial hepatectomy, remaining hepatocytes proliferate to restore liver mass within days. When hepatocyte proliferation is impaired (chronic liver disease), oval cells (bipotential progenitor cells) from the canals of Hering differentiate into both hepatocytes and cholangiocytes.
Skeletal muscle regeneration — satellite cells (PAX7+, MyoD+) reside beneath the basal lamina of muscle fibers. After injury, they proliferate as myoblasts, differentiate into myocytes, and fuse to form new myotubes. Satellite cell dysfunction underlies the progressive muscle loss in muscular dystrophies.
Cardiac regeneration — the adult heart has very limited regenerative capacity. Cardiomyocyte turnover is ~1% per year at age 25, declining to ~0.3% at age 75. Cardiac stem cells (c-KIT+) are rare and their contribution to regeneration remains controversial. Current therapy relies on transplantation (heart transplant) rather than regeneration.
Regenerative Medicine
Cell therapy — transplantation of stem cells or their derivatives to replace damaged tissue. Hematopoietic stem cell transplantation (bone marrow transplant) is the most established stem cell therapy. Mesenchymal stem cells (MSCs) from bone marrow or adipose tissue are tested in clinical trials for graft-versus-host disease, myocardial infarction, and osteoarthritis.
Tissue engineering — combining stem cells with scaffolds (natural or synthetic biomaterials) to create functional tissue constructs. Examples include artificial skin (autologous keratinocytes on collagen matrix), engineered bladder (autologous cells on biodegradable scaffold), and tracheal reconstruction (MSCs on decellularized donor trachea).
Organoids — three-dimensional stem cell-derived structures that recapitulate organ architecture and function. Intestinal, cerebral, liver, kidney, and pancreatic organoids are used for disease modeling, drug testing, and personalized medicine. Histological sectioning and staining of organoids confirms differentiation into appropriate cell types and tissue organization.
Ethical and Safety Considerations
Teratoma formation — pluripotent stem cells (ESCs, iPSCs) form teratomas if undifferentiated cells persist after transplantation. Immune rejection — autologous iPSCs avoid rejection but are costly and time-consuming to produce; allogeneic “universal donor” iPSCs require HLA engineering. Genetic instability — iPSCs accumulate genetic and epigenetic abnormalities during reprogramming and culture. Regulatory oversight by national authorities (FDA, EMA) governs clinical applications of stem cell therapies. Quality assurance in stem cell manufacturing includes sterility, purity, potency, and identity testing for each product lot.
